Kenvue slipped 1.3% to US$19.31 after posting Q3 2026 earnings, a muted move for a global consumer health group that sells everyday essentials found in millions of bathrooms and medicine cabinets. The quarter showed Basic EPS of about US$0.22 on revenue of roughly US$3.9b, with profits tracking in line with the trailing twelve month earnings run rate.
Short term traders see a slightly softer print and have marked the stock down. Longer term holders are more focused on whether this margin profile and earnings base can support the current P/E relative to both peers and the broader personal products industry.
If you appreciate the resilience in Kenvue’s everyday brands but are cautious that a flat earnings run rate might limit the price you can justify paying on P/E, compare this result with a list of solid balance sheet and fundamentals stocks (24 results) to see how other quality consumer names stack up on profitability and financial robustness.
Q3 2026 Earnings Summary
- Revenue (Q3 2026 vs Q3 2025): US$3,886m vs. US$3,764m (up 3.2%)
- Net Income (Excl. Extra Items, Q3 2026 vs Q3 2025): US$430m vs. US$398m (up 8.0%)
- Basic EPS (Q3 2026 vs Q3 2025): US$0.2238 vs. US$0.2075 (up 7.9%)
- Trailing Net Profit Margin (Last 12 Months vs Prior Year): 10.9% vs. 9.5% (higher profitability on recent earnings)
Ask Charlie what Kenvue’s valuation gap really tells investors.
Kenvue’s scale story meets early cost milestones
For the bullish view to hold, Kenvue needs its efficiency push to feed through to profitability, not just headlines.
"Strategic focus on streamlining operations, including reducing internal complexity and concentrating resources on best-selling brands and key regions, is expected to unlock cost efficiencies, improve decision-making speed and support better net margins and earnings over time."
Q3 points in the right direction. Net sales grew 3.2% with organic growth of 2.9%, while trailing net profit margin sits at 10.9% versus 9.5% the prior year. Portfolio reshaping, such as the Stayfree and Carefree disposal, backs the claim that Kenvue is simplifying around core franchises.
Deal, legal and brand risks still shadow Kenvue
On the risk side, the big question is whether heavy cost targets and legal noise start to erode the same earnings base bulls rely on.
"The combined company is counting on a US$2.1b EBITDA synergy program on top of an already ambitious productivity target of more than US$3b in cost of goods sold savings by 2030. If these cost programs prove harder to execute than expected or disrupt operations, the result could be lower than anticipated net margins and weaker earnings progress."
Q3 margins improved and EPS was only slightly below consensus, so disruption is not yet evident. That said, revived Tylenol litigation and Neutrogena backlash remain unresolved and could still offset the targeted synergy benefits.
That disagreement has a full argument behind it. → Uncover the higher Fair Value this Narrative argues for.
Hunt Quiet Mispricings Before They Close
Kenvue’s steady earnings base shows how a calm quarter can still leave big questions hanging over valuation. The real opportunity could be spotting stocks where fundamentals and pricing quietly drift apart before the gap narrows.
- Company 1 - 28% below our estimate - expands digital banking, insurance and payments so underbanked customers shift everyday money habits into higher margin fee and lending products.
- Company 2 - 38% below our estimate - grows a once niche drink into a mainstream staple as retailers hand over more shelf space to both branded and private label cartons.
- Company 3 - 35% below our estimate - sells the chips and software stack cloud operators standardize on when they rewire data centers to chase higher returns from AI training workloads.
Three companies from the same screener. Open all 30 potentially undervalued companies →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com